• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Biotech Market
Biotech News
Biotech Stocks
  • Biotech Market
  • Biotech News
  • Biotech Stocks

5 Top NASDAQ Biotech Stocks: Alkermes PLC Leads

Written by Emma Harwood
|
Oct. 23, 2016 07:40PM PST

Last week’s top gainer was Alkermes PLC, followed by Eiger BioPharmaceuticals, Concordia International, MannKind Corp. (D) and Tetraphase Pharmaceuticals.

The NASDAQ Biotechnology index (INDEXNASDAQ:NBI) had a good week. The increase in average life expectancy, lifelong reliance on healthcare and constant innovation in the industry means the index is always somewhat supported long term. As of Friday, the index was up by 0.92 percent with 2,800.90 points.
Looking at the week’s gainers, companies weren’t quite able to break much higher than 30 percent in gains for the week. Included among last week’s top gainers were:

  • Alkermes PLC (NASDAQ:ALKS)
  • Eiger BioPharmaceuticals (NASDAQ:EIGR)
  • Concordia International (NASDAQ:CXRX)
  • MannKind Corp. (D) (NASDAQ:MNKD)
  • Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Alkermes PLC
Alkermes PLC is a biopharmaceutical company, headquartered in Dublin, that focuses on central nervous system diseases. They recently announced positive results for antidepressants for those suffering from major depressive disorder (MDD) who weren’t responding to their current medication.
Alkermes PLC gained 31.49 percent over the five-day trading period and finished at $55.62 per share.
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals clinically tests original products to treat rare diseases. They recently announced the first dosage given to a patient who needs to be treated for hepatitis D virus (HDV).
Eiger BioPharmaceuticals gained 27.06 percent over the five-day trading period and finished at $14.37 per share.
Concordia International
Concordia International is a Canadian pharmaceutical company focusing on ADHD, asthma and cancer. CEO Mark Thompson recently announced his resignation.
Concordia International gained 27.07 percent over the five-day trading period and finished at $4.48 per share.

MannKind Corp. (D)
MannKind Corp. (D) is a biopharmaceutical company that focuses on cancer and diabetes. Their financial results for the first half of 2016 saw expenses down 15 percent from the previous year.
MannKind Corp. (D) gained 18.25 percent over the five-day trading period and finished at $0.594 per share.
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals fight antibiotic resistance. They recently dosed the first patient with a drug hopefully treating fatal bacterial infections.
Tetraphase Pharmaceuticals gained 17.11 percent over the five-day trading period and finished at $3.97 per share.
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Emma Harwood, hold no direct investment interest in any company mentioned in this article.
Related reading:
5 Top NASDAQ Stocks: ContraVir Pharmaceuticals Gains 63 Percent
ekso bionics holdings cellectar biosciences china
The Conversation (0)

Go Deeper

AI Powered
Microscopic view of stem cells.

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch in 2026

Latest News

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Government approvals secured for the use of Galidesivir as a treatment for Bundibugyo Ebola epidemic in Africa

Lexaria Updates Business Development

Lexaria Updates Business Development

More News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Biotech Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES